CH637124A5 - Antibiotic, its preparation and use - Google Patents
Antibiotic, its preparation and use Download PDFInfo
- Publication number
- CH637124A5 CH637124A5 CH1077678A CH1077678A CH637124A5 CH 637124 A5 CH637124 A5 CH 637124A5 CH 1077678 A CH1077678 A CH 1077678A CH 1077678 A CH1077678 A CH 1077678A CH 637124 A5 CH637124 A5 CH 637124A5
- Authority
- CH
- Switzerland
- Prior art keywords
- cyclosporin
- antibiotic
- strain
- ether
- acetone
- Prior art date
Links
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 3
- ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 claims abstract description 49
- ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 claims abstract description 49
- 108010019249 cyclosporin G Proteins 0.000 claims abstract description 49
- 230000002538 fungal effect Effects 0.000 claims abstract description 11
- 241001149960 Tolypocladium inflatum Species 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 7
- 235000015097 nutrients Nutrition 0.000 claims abstract description 7
- 238000009826 distribution Methods 0.000 claims abstract description 6
- 230000000274 adsorptive effect Effects 0.000 claims abstract description 5
- 238000000855 fermentation Methods 0.000 claims abstract description 5
- 230000004151 fermentation Effects 0.000 claims abstract description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 12
- ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- 108010019594 cyclosporin D Proteins 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000004458 analytical method Methods 0.000 claims description 8
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 7
- 229930105110 Cyclosporin A Natural products 0.000 claims description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 6
- 108010036949 Cyclosporine Proteins 0.000 claims description 6
- 229960001265 ciclosporin Drugs 0.000 claims description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- KDCIHNCMPUBDKT-UHFFFAOYSA-N hexane;propan-2-one Chemical compound CC(C)=O.CCCCCC KDCIHNCMPUBDKT-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- 108010077895 Sarcosine Proteins 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 claims description 4
- 238000000921 elemental analysis Methods 0.000 claims description 4
- 230000008030 elimination Effects 0.000 claims description 4
- 238000003379 elimination reaction Methods 0.000 claims description 4
- 238000001819 mass spectrum Methods 0.000 claims description 4
- 229940043230 sarcosine Drugs 0.000 claims description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 4
- 239000000741 silica gel Substances 0.000 claims description 4
- 229910002027 silica gel Inorganic materials 0.000 claims description 4
- JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 claims description 3
- JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 claims description 3
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 claims description 3
- 108010019248 cyclosporin C Proteins 0.000 claims description 3
- GNGBSKIQPUCELM-YBAOVNABSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(e,2r)-2-methylhex-4-enyl]-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29, Chemical compound CC[C@@H]1NC(=O)[C@H](C[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-YBAOVNABSA-N 0.000 claims description 2
- UCOQITKXMNKTKF-MXGZYYNMSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28,30-decamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C)NC1=O UCOQITKXMNKTKF-MXGZYYNMSA-N 0.000 claims description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- GNGBSKIQPUCELM-UHFFFAOYSA-N Cyclosporin F Natural products CCC1NC(=O)C(CC(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-UHFFFAOYSA-N 0.000 claims description 2
- 241000233866 Fungi Species 0.000 claims description 2
- 241000364057 Peoria Species 0.000 claims description 2
- 241000123975 Trichoderma polysporum Species 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 238000004364 calculation method Methods 0.000 claims description 2
- 101150102523 cdc12 gene Proteins 0.000 claims description 2
- 238000012512 characterization method Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 108010019252 cyclosporin F Proteins 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 2
- 238000002329 infrared spectrum Methods 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 230000035772 mutation Effects 0.000 claims description 2
- 229930014626 natural product Natural products 0.000 claims description 2
- 238000012827 research and development Methods 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 claims description 2
- 238000002211 ultraviolet spectrum Methods 0.000 claims description 2
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 4
- 238000004587 chromatography analysis Methods 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 241000223211 Curvularia lunata Species 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/885—Trichoderma
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (29)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1077678A CH637124A5 (en) | 1978-10-18 | 1978-10-18 | Antibiotic, its preparation and use |
| SE7908350A SE448386B (sv) | 1978-10-18 | 1979-10-09 | Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem |
| DE19792941080 DE2941080A1 (de) | 1978-10-18 | 1979-10-10 | Neue metaboliten, ihre herstellung und verwendung |
| DK428179A DK148752C (da) | 1978-10-18 | 1979-10-10 | Fremgangsmaade til fremstilling af cyclosporinderivater |
| FI793142A FI60032C (fi) | 1978-10-18 | 1979-10-10 | Foerfarande foer framstaellning av nytt terapeutiskt verkande cyklosporin g |
| US06/084,100 US4288431A (en) | 1978-10-18 | 1979-10-12 | Cyclosporin derivatives, their production and pharmaceutical compositions containing them |
| NL7907609A NL7907609A (nl) | 1978-10-18 | 1979-10-15 | Cyclosporinederivaten en werkwijzen voor het bereiden en toepassen van deze derivaten. |
| CY1286A CY1286A (en) | 1978-10-18 | 1979-10-15 | Cyclosporin derivatives their production and pharmaceutical compositions containing them |
| BE1/9567A BE879402A (fr) | 1978-10-18 | 1979-10-15 | Nouveaux derives cyclopeptidiques, leur preparation et leur application comme medicaments |
| GB7935689A GB2033398B (en) | 1978-10-18 | 1979-10-15 | L compositions containing them cyclosporin derivatives their production and pharmaceutica |
| IT7950577A IT1164109B (it) | 1978-10-18 | 1979-10-16 | Derivati della ciclosporina loro preparazione e loro applicazione come medicamenti |
| NZ191865A NZ191865A (en) | 1978-10-18 | 1979-10-16 | Cyclosporin g, dihydro- or iso-cyclosporin g and pharmaceutical compositions |
| IL7958465A IL58465A (en) | 1978-10-18 | 1979-10-16 | Cyclosporin derivatives,their production and pharmaceutical compositions containing them |
| PT70324A PT70324A (fr) | 1978-10-18 | 1979-10-16 | Procede pour la production de nouveaux composes organiquesa effet pharmaceutique |
| AT0672679A AT375399B (de) | 1978-10-18 | 1979-10-16 | Verfahren zur herstellung des neuen therapeutisch wirksamen cyclosporin g |
| IE1967/79A IE49084B1 (en) | 1978-10-18 | 1979-10-16 | Cyclosporin derivatives,their production and pharmaceutical compositions containing them |
| JP13471079A JPS5555150A (en) | 1978-10-18 | 1979-10-17 | Cyclosporin derivatives*their manufacture and medical composition containing them |
| FR7925780A FR2439182A1 (fr) | 1978-10-18 | 1979-10-17 | Nouveaux derives cyclopeptidiques, leur preparation et leur application comme medicaments |
| PH23188A PH14086A (en) | 1978-10-18 | 1979-10-17 | Cyclosporin derivatives and pharmaceutical compositions thereof |
| ES485104A ES485104A1 (es) | 1978-10-18 | 1979-10-17 | Procedimiento para preparar derivados de ciclosporina |
| CA337,826A CA1129359A (en) | 1978-10-18 | 1979-10-17 | Cyclosporin derivatives, their production and pharmaceutical compositions containing them |
| AU51911/79A AU530379B2 (en) | 1978-10-18 | 1979-10-18 | Cyclosporins |
| ZA00795560A ZA795560B (en) | 1978-10-18 | 1979-10-18 | Cyclosporin derivatives, their production and pharmaceutical compositions containing them |
| FI811006A FI63743C (fi) | 1978-10-18 | 1981-04-01 | Foerfarande foer framstaellning av terapeutiskt anvaendbart iscyklosporin g |
| FI811005A FI63742C (fi) | 1978-10-18 | 1981-04-01 | Foerfarande foer framstaellning av terapeutiskt anvaendbart diydrocyklosporin g |
| SG146/85A SG14685G (en) | 1978-10-18 | 1985-02-27 | Cyclosporin derivatives,their production and pharmaceutical compositions containing them |
| KE3517A KE3517A (en) | 1978-10-18 | 1985-03-22 | Cyclosporin derivatives,their production and pharmaceutical compositions containing them |
| HK486/85A HK48685A (en) | 1978-10-18 | 1985-06-20 | Cyclosporin derivatives, their production and pharmaceutical compositions containing them |
| MY618/85A MY8500618A (en) | 1978-10-18 | 1985-12-30 | Cyclosporin derivatives, their production and pharmaceutical compositions containing them |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH1077678A CH637124A5 (en) | 1978-10-18 | 1978-10-18 | Antibiotic, its preparation and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH637124A5 true CH637124A5 (en) | 1983-07-15 |
Family
ID=4366764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH1077678A CH637124A5 (en) | 1978-10-18 | 1978-10-18 | Antibiotic, its preparation and use |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JPS5555150A (enrdf_load_stackoverflow) |
| AT (1) | AT375399B (enrdf_load_stackoverflow) |
| BE (1) | BE879402A (enrdf_load_stackoverflow) |
| CH (1) | CH637124A5 (enrdf_load_stackoverflow) |
| ZA (1) | ZA795560B (enrdf_load_stackoverflow) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU203564B (en) * | 1987-12-21 | 1991-08-28 | Sandoz Ag | Process for producing new orthorombos cyclosporin without solvatation |
| DE69222150T2 (de) * | 1991-01-25 | 1998-01-15 | Fujisawa Pharmaceutical Co | Prozess zur produktion von cyclosporin-a und/oder c |
-
1978
- 1978-10-18 CH CH1077678A patent/CH637124A5/de not_active IP Right Cessation
-
1979
- 1979-10-15 BE BE1/9567A patent/BE879402A/fr not_active IP Right Cessation
- 1979-10-16 AT AT0672679A patent/AT375399B/de not_active IP Right Cessation
- 1979-10-17 JP JP13471079A patent/JPS5555150A/ja active Granted
- 1979-10-18 ZA ZA00795560A patent/ZA795560B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATA672679A (de) | 1983-12-15 |
| AT375399B (de) | 1984-07-25 |
| JPS5555150A (en) | 1980-04-22 |
| JPS6340200B2 (enrdf_load_stackoverflow) | 1988-08-10 |
| ZA795560B (en) | 1981-05-27 |
| BE879402A (fr) | 1980-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2941080C2 (enrdf_load_stackoverflow) | ||
| DE2819094C2 (enrdf_load_stackoverflow) | ||
| CH638194A5 (de) | Esterastin, eine neue physiologisch wirksame substanz und deren herstellung. | |
| CH619735A5 (enrdf_load_stackoverflow) | ||
| DE2463138C2 (de) | Das Antibiotikum Cyclosporin B (S 7481/F-2), seine Herstellung und Verwendung | |
| DE3109335A1 (de) | Die neue, physiologisch wirksame substanz ebelacton und verfahren zur herstellung derselben | |
| DE69513419T2 (de) | Neues peptid und therapeutisches agens | |
| DE2954675C2 (de) | Verwendung von Polypeptiden zur Bekämpfung von Krebs | |
| DE2911353C2 (enrdf_load_stackoverflow) | ||
| AT395860B (de) | Verfahren zur herstellung eines neuen antitumor-antibiotikums und seine verwendung | |
| CH637123A5 (en) | Monocyclic peptide, its preparation and use | |
| CH630062A5 (en) | Process for the preparation of an antibiotic derivative | |
| CH630061A5 (en) | Process for the preparation of an antibiotic derivative | |
| CH637124A5 (en) | Antibiotic, its preparation and use | |
| DE2839668C2 (enrdf_load_stackoverflow) | ||
| DE10021731B4 (de) | Cyclipostine, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitung derselben | |
| DE2028403B2 (de) | Pepstatin | |
| DE2900315C2 (de) | 3"-N-Methyl-4"-C-methyl-3',4'-didesoxy-kanamycine oder deren 4"-Epimere, Verfahren zu ihrer Herstellung sowie ihre Verwendung | |
| CH640521A5 (en) | Cyclosporin D | |
| CH633826A5 (en) | Process for the preparation of a novel antibiotic | |
| DE69214737T2 (de) | Antibiotika NK374186A, NK374186B, NK374186B3 und NK374186C3, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| CH603790A5 (en) | Antibiotics S 7481-F-1 and 2 | |
| CH642954A5 (en) | Isocyclosporin G, its preparation and medicaments containing it | |
| DE2645528C3 (de) | Antibiotisch wirksame Pyrrole [2,1c] -1,4benzdiazepine | |
| DE2316429A1 (de) | Verfahren zur herstellung eines neuen metaboliten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PFA | Name/firm changed |
Owner name: SANDOZ AG TRANSFER- NOVARTIS AG |
|
| PL | Patent ceased |